-
Mashup Score: 8
Title: The Best Cancer Is The Cancer That Never HappensPhilip Castle, PhD, MPHDirector of the Division of Cancer PreventionNational Cancer InstituteLearn mor…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
The addition of concurrent cisplatin-based CT to RT significantly improves progression-free and overall survival for high-risk, early-stage patients who undergo radical hysterectomy and pelvic lymphadenectomy for carcinoma of the cervix.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver - 3 month(s) ago
Nature – Structural changes mediated by advanced glycation end-products enhance extracellular matrix viscoelasticity, and that viscoelasticity can promote cancer progression in vivo, independent of…
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 8Advances in translational research of the rare cancer type adrenocortical carcinoma - PubMed - 3 month(s) ago
Adrenocortical carcinoma is a rare malignancy with an annual worldwide incidence of 1-2 cases per 1 million and a 5-year survival rate of <60%. Although adrenocortical carcinoma is rare, such rare cancers account for approximately one third of patients diagnosed with cancer annually. In the past …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4Stem-Cell Aging and Pathways to Precancer Evolution - PubMed - 4 month(s) ago
Stem-Cell Aging and Pathways to Precancer Evolution
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4
PURPOSE Identification and documentation of Veterans’ symptoms are crucial for optimal lung cancer care delivery. The objective of this study was to determine whether a volunteer-led proactive telephone symptom assessment intervention could improve comprehensive symptom documentation. METHODS Veterans with lung cancer were randomly assigned to usual care (control group) or usual care with proactive symptom assessment in which a peer volunteer made weekly phone calls to assess patient symptoms under nurse practitioner supervision. The primary outcome was oncologist documentation of symptoms in the electronic health record at all clinical visits within 6 months after enrollment. Secondary outcomes included patient satisfaction with decision, patient activation, health-related quality of life (HRQOL), and symptom burden, measured at baseline, and 3, 6, and 9 months after enrollment, and acute care use within 9 months after enrollment. RESULTS Among 60 Veterans randomly assigned, median (r
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 16Stanford | Faculty Positions: Details - Assistant Professor, Early Drug Development - 4 month(s) ago
Apply now Work type: University Tenure Line Location: Stanford University Categories: School of Medicine The Stanford Cancer Institute (SCI) at the Stanford University School of Medicine seeks applicants to join our Early Drug Development (EDD) Program as an Assistant Professor in the University Medical Line (UML) or University Tenure Line (UTL). The successful candidate should be a…
Source: facultypositions.stanford.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Individualized Stereotactic Ablative Radiotherapy for Lung Tumors - 5 month(s) ago
This nonrandomized controlled trial of patients diagnosed with non–small cell lung cancer assesses whether individualizing stereotactic ablative radiotherapy dose and fractionation by tumor size, location, and histological characteristics may be associated with local tumor control and the rate of…
Source: jamanetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 14
Nature – Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 102023 American Society of Hematology Annual Meeting & Exposition - 5 month(s) ago
Stanford is excited to have 26 presenters at this year’s ASH Annual Meeting & Exposition. The Stanford Cancer Institute will also be hosting a booth at this year’s conference.
Source: med.stanford.eduCategories: General Medicine News, Oncologists1Tweet
Philip Castle from @theNCI was our distinguished speaker at Feb's SCI Breakthroughs in Cancer seminar. Watch 'The Best Cancer Is The Cancer That Never Happens' here: https://t.co/kl2AvPvZfl. @NCICastle #CancerPrevention Don't miss March's talk by Paul Buckley from @fredhutch.